Viatris And Biocon Line Up EU Bevacizumab
As Accord Receives Positive CHMP Opinion For Abiraterone
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
You may also be interested in...
Viatris has bounced back from withdrawing its application for a generic version of Gilenya in the EU with a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.